anoth solid quarter revenu come ahead
vs street rais full year guidanc
suggest revenu growth constant currenc revenu
growth suggest stabl comp adjust trend us growth
acceler comp adjust basi ad record number new
patient new patient funnel remain healthi suggest continu
momentum back half next year street expect growth
increasingli look conserv view reiter
timelin initi launch late full launch
payment verili quarter suggest dxcm partner deliv rais
po base revenue base revenue
reiter buy rate
gross margin ramp look steep doabl
gross margin expect roughli
approach roughli ramp first half
expect come two thing absorpt higher volum natur occur
lower cost transmitt histor dxcm gross margin
anywher higher first half suggest natur trend
better gross margin addit math lower cost transmitt
suggest could see upward pressur gross margin
alon estim transmitt today carri roughli gross margin
expect cut cost good sold half suggest
save cost good sold line full year basi
net dbt
growth stori track rais po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim launch medicar
conserv assumpt util price
competit could drive upsid near term
long-term penetr non-intens type
increas total avail market opportun
also believ cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
valu ev/sal given compani trade revenu growth
price object base revenu estim multipl line
small mid-cap med-tech compani similar revenu growth rate
market opportun
upsid risk strateg activ patient expect less impact
expect competit faster approv pipelin product
downsid risk price pressur fewer patient added/high attrit current
patient due competitor threat lack patient want adopt cgm delay
pipelin product
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
